Study links surgery medicines to the stomach tumor environment
Part of Cancer, Digestive system clinical trials.
This trial looks at how medicines given around the time of stomach cancer surgery may change the “tumor microenvironment,” which is the biology around the tumor. It may help doctors better understand which perioperative treatments work best for locally advanced, operable stomach cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed locally advanced stomach (or stomach–esophagus junction) adenocarcinoma that can be surgically removed, with no distant metastases
- You’re 18 to 75 years old
- You can provide leftover tumor tissue after your usual diagnosis for special tumor-environment testing
- You plan to receive medicines during the perioperative (around-surgery) period
- Your overall health/activity level is ECOG 0 or 1 (generally fully active or limited but ambulatory)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is looking at whether giving extra treatment after surgery for stomach cancer can help lower the chance of it coming back. It is for people who had a specific kind of chemotherapy and immunotherapy before surgery and then had their stomach removed.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This study looks at tissue samples from stomach or gastroesophageal junction cancer to understand how the tumor interacts with its surroundings, which may help predict if the cancer will resist treatment. All participants will receive standard chemotherapy (FLOT) plus durvalumab before and after surgery.
This trial tests if surgery to remove visible cancer in the belly combined with heated chemotherapy placed directly into the abdomen can help people with stomach cancer that has spread to the lining of the belly. It is for patients who are well enough to undergo major surgery and meet specific health requirements.
This trial tests a combination of immunotherapy drugs (sintilimab, chemotherapy, and sometimes ipilimumab) given before surgery to shrink stomach or esophageal junction tumors, then continued after surgery. The goal is to improve survival in patients with resectable (removable) gastric or gastroesophageal junction cancer.
This trial tests a new combination of low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX) given before surgery for locally advanced gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink tumors more effectively.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.